Teva's ANDA Submission for Canagliflozin Receives TA Status
Teva Pharmaceuticals has submitted an ANDA for Canagliflozin, currently under standard review with TA status.
Published: July 24, 2026
Updated: July 24, 2026
Author: Humanexa Intelligence
Therapeutic area: Diabetes / SGLT2 Inhibitor
Company: Teva
Asset: Canagliflozin
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Teva
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Teva's ANDA submission for Canagliflozin with TA status marks a significant competitive entry into the SGLT2 inhibitor market. This could disrupt pricing and market share dynamics, necessitating a strategic response from existing players.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the review progress and any upcoming decisions from the FDA regarding this ANDA submission.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.